Results 151 to 160 of about 51,453 (260)

Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression

open access: yesAdvanced Science, EarlyView.
This study uncovers a new oncogenic mechanism in melanoma. The transcription factor PATZ1 competes with the architectural protein CTCF for DNA binding, thereby disrupting a specific chromatin loop and silencing the tumor suppressor ZBTB20. This event unleashes the pro‐tumorigenic PMEPA1‐p38‐STAT1 signaling axis, promoting cancer progression.
Chaowei Deng   +8 more
wiley   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo   +6 more
wiley   +1 more source

ZSL Orchestrates Synaptonemal Complex Assembly as a Central Region Scaffold to Ensure Synapsis Fidelity and Crossover Control in Polyploid Meiosis

open access: yesAdvanced Science, EarlyView.
A central molecular adaptor, ZSL, is identified that links transverse filaments ZYP1 to central element SCEP1/2 to drive synaptonemal complex assembly in Brassica napus. Loss of ZSL abolishes synaptonemal complex formation, disrupts meiotic chromosome segregation, and markedly increases crossovers, providing mechanistic insight into meiotic fidelity ...
Miaowei Geng   +16 more
wiley   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance. [PDF]

open access: yesDiscov Oncol
Ramalingam PS   +12 more
europepmc   +1 more source

Loss of VMP1 Impairs Tight Junction Recycling and Aggravates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
This study identifies vacuole membrane protein 1 (VMP1) as a critical regulator of intestinal epithelial barrier homeostasis. VMP1 facilitates the recruitment of CORO1C to late endosomes, supporting Retromer‐mediated recycling of the tight junction protein Occludin.
Jiawei Zhao   +12 more
wiley   +1 more source

ZMAT1 Promotes Osteoclastogenesis Through TRIM46 Mediated YAP1 Degradation and Inhibits Osteoblastogenesis

open access: yesAdvanced Science, EarlyView.
Zmat1 deficiency mitigates pathological bone loss by impairing osteoclastogenesis and promoting osteoblastogenesis. Mechanistically, in osteoclasts, Zmat1 loss relieves transcriptional repression of the E3 ligase TRIM46, promoting YAP1 degradation and inhibiting osteoclastogenic genes.
Xinyu Chang   +13 more
wiley   +1 more source

Artesunate Ameliorates APAP‐induced Liver Injury by Promoting NEDD4L‐Mediated Ubiquitination and Degradation of TXNIP

open access: yesAdvanced Science, EarlyView.
ABSTRACT Liver injury can lead to severe acute liver failure and even death in patients. Artesunate (ART), which is a derivative of artemisinin that has been approved by the FDA for the treatment of malaria, has significant regulatory effects on cell death and inflammation.
Zhe Zhang   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy